START Center for Cancer Research

The organization conducts preclinical and early-phase clinical trials of novel anti-cancer agents on behalf of pharmaceutical customers, bringing high-quality research standards typically associated with top academic medical centers into the community oncology setting. START has conducted more than 1,000 early-phase clinical trials across its global network of community oncology centers. In 2024, START received investment from Warburg Pincus, a major private equity firm, signaling growth and expansion ambitions. For nurses, START offers a specialized environment focused on Phase 1 clinical trial work rather than traditional inpatient or outpatient nursing. Roles such as Nurse Navigator involve serving as the primary liaison between patients, referring physicians, and START staff, ensuring timely and coordinated care while addressing barriers to trial participation. Clinical research nursing duties include venipuncture, IV insertion, venous access device procedures, and obtaining blood specimens for study-related activities. The company employs 201 to 500 people and operates under CEO Nick Slack, MBE, who holds a 40% CEO approval rating. The organization provides nurses with exposure to cutting-edge oncology therapeutics and clinical trial methodology, though workplace reviews indicate notable challenges in areas such as management support, job security, and compensation.

START's mission centers on providing access to specialized preclinical and early-phase clinical trials of novel anti-cancer agents in the community oncology setting, where the vast majority of cancer patients are treated. The organization aims to bring the high-quality research standards of top academic medical centers to community-based cancer care, advancing cancer treatment through rigorous clinical research. Employees report appreciating a clear sense of purpose and the ability to meet personal goals, suggesting the mission resonates with staff.